secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008907
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns announces $1.0B cash runway; TERN-701 pivotal trial planned late 2026/early 2027
--------------------------------------------------------------------------------

- Year-end 2025 unaudited cash ~$1.0B, expected to fund operations into 2031 including potential TERN-701 launch.
- Completed December 2025 public offering of 18.7M shares, gross proceeds ~$747.5M.
- TERN-701 granted FDA Fast Track for CML; CARDINAL trial enrolled 85+ patients as of Dec 8, 2025.
- 2026 milestones: pivotal dose selection and EOP2 FDA interaction mid-2026; updated CARDINAL data by 2H26; start 2L+ pivotal trial late 2026/early 2027.
- New CARDINAL cohort to evaluate TERN-701 500mg QD in patients with BCR-ABL mutations including T315I.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312526008907/0001193125-26-008907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312526008907/d69982d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer